Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 7721-7730 Newer>

The Motley Fool June 3, 2005 Seth Jayson	Happy Returns in Retail Maybe it's time to look past the top line. Is Pacific Sunwear worth a look for investors?
The Motley Fool June 3, 2005 Tim Beyers	Let's Hear It for Joe Oddlot Don't let anyone tell you that you need to be on Wall Street to be a superior investor. You don't. Think you can't possibly beat the market, right? Balderdash.
The Motley Fool June 3, 2005 Jeremy MacNealy	A Heroic Effort From Hurco Second-quarter results include record numbers for the industrial technology company. With growth like this, it's hard to argue that this enterprise is grossly overvalued.
The Motley Fool June 3, 2005 Stephen D. Simpson	A Noble Deal Is this the start of a more prolonged rise for oil drillers? While investors need to be careful about stock selection (and remember that these are cyclical companies), so long as day rates keep rising, the stocks should follow.
The Motley Fool June 3, 2005 Rich Smith	Titan(ic) Surfaces Unscathed L-3 catches Titan on rebound from Lockheed breakup. Investors, take note.
The Motley Fool June 3, 2005 Nathan Slaughter	Rex Rocks -- Still No Best Buy Smaller electronics retailer posts a 50% jump in first-quarter earnings but poses no threat to the major players.
The Motley Fool June 3, 2005 Stephen D. Simpson	Harvest of Sorrows In an ongoing attempt to squeeze foreign oil companies, the Venezuelan government has once again unilaterally and retroactively changed the rules of the game. Harvest Natural Resources suffers. Investors, take note.
The Motley Fool June 3, 2005 Rich Duprey	Cantel Is Dealt an Olympic Blow The termination of a distribution agreement knocks the medical equipment company down 40%.
The Motley Fool June 3, 2005 Selena Maranjian	Reduce Your Investing Risk A few changes in your investing M.O. can improve your performance.
The Motley Fool June 3, 2005 Brian Gorman	Merck's New Innovation Pending FDA approval, the company's experimental shingles vaccine will probably be a steady earner. In the near term, the stock isn't going to see huge gains, but the company is here to stay and will keep innovating.
<Older 7721-7730 Newer> Return to current articles.